Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patientsâ lives. Aptevo has a commercial product, IXINITYÂŽ coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology â the ADAPTIR⢠modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases. Source
No articles found.
We are a patient-centric, clinical-stage biopharmaceutical company dedicated to br...
We are a patient-centric, clinical-stage biopha...
With a focus on the development of small molecule drugs for the treatment of cance...
With a focus on the development of small molecu...
Synlogic⢠is pioneering the development of a novel class of living Synthetic Bio...
Synlogic⢠is pioneering the development of a ...
Histogenics historically focused on the development of restorative cell therapies,...
Histogenics historically focused on the develop...
InMode Ltd. (Nasdaq: INMD) is a leading global provider of innovative medical tech...
InMode Ltd. (Nasdaq: INMD) is a leading global ...
Avinger is a commercial-stage medical device company that designs, manufactures an...
Avinger is a commercial-stage medical device co...
Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing ...
Trillium Therapeutics Inc. is a clinical stage ...
Cancer is one of the most difficult diseases to treat. It is constantly changing, ...
Cancer is one of the most difficult diseases to...
Mustang Bio, Inc. (âMustangâ), a Fortress Biotech Company, is a clinical-stage...
Mustang Bio, Inc. (âMustangâ), a Fortress B...
Tyme Inc. is an emerging biotechnology company developing cancer therapeutics that...
Tyme Inc. is an emerging biotechnology company ...
Join the National Investor Network and get the latest information with your interests in mind.